NanoString Breast Cancer Intrinsic Subtyping Assay update

NanoString began a validation study to evaluate its NanoString Breast Cancer Intrinsic Subtyping Assay on 1,000 samples from post-menopausal women with hormone receptor-positive, early stage breast ca...